Can a Child Receive a Second Bone Marrow Transplant?
A second bone marrow transplant — also called second haematopoietic cell transplantation, or second HCT — is possible in selected children, but it is a significant medical decision. It depends on why the first transplant failed, the child's current disease status and organ function, and whether a specialist team believes it offers a meaningful chance of durable remission. Not every child is a candidate; the decision requires careful, individualised MDT assessment.
For families in this situation
If your child has relapsed after bone marrow transplant, or if the transplant has not engrafted, you are likely in one of the most difficult moments a family can face. This article is intended to provide clear, honest information about what is medically possible — including both second transplant and alternatives — to help you ask the right questions and understand what a specialist assessment would involve.
When Is a Second Transplant Considered for a Child?
There are three main clinical scenarios in which a second transplant may be discussed for a child who has already received a bone marrow or stem cell transplant.
1Relapse after a first allogeneic transplant
The most common reason a second transplant is considered. Disease — typically leukaemia — returns after an initial period of remission post-transplant. Relapse after HCT is a serious situation. Whether a second transplant is appropriate depends heavily on:
- Timing: relapse within 6 months of first transplant carries a much poorer prognosis than relapse after 12+ months
- Disease burden: how much disease has returned, and how aggressive it is
- Disease type: leukaemia subtype, molecular profile, and prior treatment history
- Whether remission can be re-achieved: a second transplant performed in active disease has significantly worse outcomes than one performed in remission
Before deciding on a second transplant for relapse, the medical team will typically assess whether DLI, CAR-T, or salvage chemotherapy can bring the disease back into remission first — then consider whether second HCT consolidation makes sense.
2Primary graft failure
The donated cells never established normal blood cell production in the child's bone marrow — engraftment did not occur. This is a medical emergency. A second transplant is typically required, often with a different donor and different conditioning regimen. Primary graft failure is relatively uncommon with modern conditioning protocols but remains a recognised complication, particularly with cord blood transplant, heavily HLA-mismatched donors, or patients with aplastic anaemia and immune rejection.
When primary graft failure occurs, the second transplant decision is usually urgent and straightforward in principle — the question is finding the right donor and conditioning approach quickly.
3Secondary (late) graft failure
The transplant initially engrafted, but the graft has subsequently failed — blood counts decline, chimerism shows falling donor contribution, and the child's own bone marrow is no longer being replaced by the donor graft. Secondary graft failure can occur months to years after a successful first transplant, and may reflect immune rejection, relapsed disease interfering with the graft, infection, or other causes.
The management depends on the underlying cause. If relapsed disease is driving graft failure, disease-directed therapy is needed first. If graft failure is immune-mediated, a second transplant — sometimes with reduced conditioning — may be the primary intervention.
What Determines Whether a Child Is a Candidate for a Second Transplant?
Second transplants carry higher treatment-related mortality than first transplants. A child who has already been through conditioning chemotherapy and/or radiation, a full transplant, and potentially months of complications carries a greater burden of cumulative toxicity. The specialist team must carefully weigh the risk of the second transplant against the expected benefit.
Disease status at the time of second transplant
Being in complete remission (CR) at the time of second transplant significantly improves outcomes compared to transplanting in active or partially controlled disease. Achieving CR before second transplant — through DLI, CAR-T, or salvage chemotherapy — is a key goal.
Timing of relapse after first transplant
Late relapse (>12 months after first transplant) is associated with better outcomes after second transplant than early relapse (<6 months). Very early relapse — particularly within the first few months — indicates biologically aggressive disease that may not respond to second transplant.
Cumulative organ toxicity
Prior conditioning chemotherapy (especially busulfan, cyclophosphamide, or total body irradiation) and the transplant course itself accumulate toxicity in the liver, lungs, heart, and kidneys. Assessment of organ function guides whether a second conditioning regimen is safe.
Performance status and overall fitness
A child who is significantly debilitated by prior treatment, chronic GvHD, infections, or disease burden is a higher-risk candidate for second transplant. Fitness assessment is an essential part of the pre-transplant evaluation.
Disease biology and response history
Some disease subtypes — certain high-risk AML subgroups, for example — have historically poor outcomes even with second transplant. The specific molecular and cytogenetic features of the disease inform the likelihood of durable remission after a second transplant.
Available donors
A change of donor is usually recommended for second transplant after relapse. The availability of a new donor — haploidentical family member, different unrelated donor — determines what options are logistically feasible.
What Options Are Considered Before or Instead of a Second Transplant?
A second transplant is rarely the immediate first response to relapse or graft failure. Several interventions may be attempted first — to bring the disease under control, to restore graft function, or as definitive treatment in their own right.
Donor Lymphocyte Infusion (DLI)
DLI involves infusing additional lymphocytes (immune cells) from the original transplant donor to stimulate a graft-versus-leukaemia (GvL) immune effect against the relapsed disease. It does not require a new conditioning regimen and is given as an outpatient or short-stay procedure.
DLI is most effective when:
- The child still has a functioning graft from the original donor (confirmed by chimerism testing)
- Relapse is late (>6 months from transplant) and disease burden is low
- The disease type has known DLI sensitivity (some leukaemia subtypes respond better than others)
- The original donor was not haploidentical (DLI from haploidentical donors carries a higher GvHD risk)
The principal risk of DLI is inducing GvHD. DLI is not appropriate for rapidly progressive or high-burden relapse — in those situations, the disease needs urgent disease-directed therapy, not immune modulation alone.
CAR-T Cell Therapy — as a Bridge to Second Transplant or as Definitive Treatment
For children with CD19+ or CD22+ B-cell acute lymphoblastic leukaemia (B-ALL) who relapse after transplant, CAR-T cell therapy is an important option. Multiple NMPA-approved CAR-T products are available in China for paediatric B-ALL.
CAR-T after prior transplant may be used in two ways:
- As a bridge to second transplant: achieving deep remission (MRD-negative CR) with CAR-T, then proceeding to second HCT for consolidation and long-term disease control
- As definitive treatment: in selected cases where second transplant is not feasible or not preferred, sustained remission with CAR-T alone has been reported — though durability without consolidation transplant varies significantly by case
The CAR-T & Cell Therapy hub covers access pathways, eligibility assessment, and logistics for children seeking CAR-T in China after a failed transplant.
Salvage Chemotherapy and Targeted Agents
Before committing to a second transplant, systemic treatment — chemotherapy, targeted agents, or bispecific antibodies — is typically used to reduce disease burden and achieve remission. For B-ALL, blinatumomab (a CD3/CD19 bispecific T cell engager) is used in some relapsed settings. For AML, agents depend on the specific mutation profile. The goal is to reach remission before the second transplant, which significantly improves outcomes.
When a Second Transplant Is Not Appropriate
Honest assessment includes recognising when second transplant is not in the child's best interest — because organ function is too compromised, disease is too aggressive to be controlled even temporarily, or the expected burden of second transplant is disproportionate to realistic benefit. In these situations, palliative and supportive care — focused on quality of life and symptom control — is the appropriate priority.
This is one of the most difficult conversations families face, and a structured second opinion helps ensure the decision is made with full information from an experienced specialist perspective — not just from a centre that may have limited experience with complex paediatric second transplants.
Facing relapse or graft failure after your child's first transplant?
A structured case review with Chinese paediatric haematology and transplant specialists can evaluate whether a second transplant, DLI, CAR-T, or another approach is most appropriate — without requiring travel first.
Request a specialist case reviewWhat Is Different About a Second Transplant?
A second transplant is not simply a repeat of the first. Several key elements typically change.
Donor change
When relapse is the reason for a second transplant, using the same donor again is generally not recommended — the first donor's immune system failed to control disease long-term. A different donor, often a haploidentical family member (parent, sibling) if the first donor was matched unrelated or matched sibling, introduces a new immune repertoire with potentially stronger graft-versus-leukaemia (GvL) effect. The specific mismatch characteristics of the new donor may be chosen deliberately to maximise GvL.
Reduced-intensity or different conditioning
Because the child has already received prior conditioning and cumulative treatment toxicity is higher, a second conditioning regimen must balance disease eradication with manageable toxicity. Reduced-intensity conditioning (RIC) is often used in second transplant to reduce organ toxicity, with reliance on graft-versus-leukaemia effect rather than high-dose chemotherapy for disease control.
Pre-transplant MRD assessment
Minimal residual disease (MRD) testing — assessing whether disease is truly in remission at a molecular level, not just by standard imaging — is standard before a second transplant. Proceeding to second HCT with MRD-positive disease significantly reduces the probability of long-term success.
More complex supportive care
Children who have had a prior transplant have a different baseline — possibly chronic GvHD from the first graft, prior infection history, immune reconstitution at a different point, and higher rates of certain complications. Supportive care during second transplant must be adapted accordingly.
Why Chinese Paediatric Haematology Centres Are Relevant for Second Transplant Cases
This article is part of ChinaMed Waypoint's paediatric leukaemia and blood disorders resources for international families facing relapse, refractory disease, or complex transplant decisions. Second transplant cases — particularly those involving donor change, haploidentical strategy after a prior matched transplant, or CAR-T bridging — are among the most complex in paediatric haematology.
Chinese paediatric haematology centres have several relevant characteristics for families in this situation:
Large haploidentical second transplant experience
Switching from a matched donor to a haploidentical family member for a second transplant — a strategy that introduces a new immune response against leukaemia — has been extensively studied at Chinese centres. The Beijing Protocol, developed at Peking University Institute of Haematology, supports this strategy with published outcomes data across multiple indications.
CAR-T followed by second transplant sequencing
The sequence of CAR-T therapy to achieve remission followed by consolidation haploidentical second transplant is an area of active clinical experience in China. For children with relapsed B-ALL after prior HCT, this pathway has been used at major Chinese centres with published outcomes.
Structured remote evaluation
An online MDT consultation allows a Chinese specialist team to review the child's full clinical history — first transplant, relapse documentation, current disease status, prior organ toxicity, and available donors — and provide a concrete recommendation on whether second transplant, DLI, CAR-T, or a combined approach is most appropriate. This does not require travel.
For further context on available donor alternatives for a second transplant, see the guide to options when no matched donor is available — including how haploidentical donors are evaluated for a second transplant.
Supportive Care for Children Facing a Second Transplant
Children preparing for or recovering from a second transplant — and their families — face an exceptionally demanding period. Supportive care that addresses physical, nutritional, and emotional needs alongside the primary medical treatment is important and not secondary.
Related Guides
What Are the Options When Leukemia Comes Back After Transplant?
DLI, CAR-T, salvage chemotherapy, and second transplant — a decision framework for families facing post-transplant relapse.
CAR-T & Cell Therapy in China
CAR-T access, eligibility, and pathways for children with relapsed or refractory haematological malignancies in China.
What Are the Options When No Matched Unrelated Donor Is Available?
Haploidentical family donors, cord blood, and mismatched donors — alternatives when a matched registry donor cannot be found for a second transplant.
Frequently Asked Questions
Can a child have a second bone marrow transplant?
Yes, a second bone marrow or stem cell transplant (second HCT) can be performed in selected children. It is most commonly considered when a child relapses after a first transplant and disease can be brought back into remission, or when the first transplant fails due to graft failure. Not every child is a candidate — second transplants carry higher treatment-related risks than first transplants, and careful assessment of disease status, organ function, and overall fitness is required before proceeding.
How soon after relapse should a second transplant be considered?
There is no fixed timeline. The urgency and approach depend heavily on the disease type and rate of progression. For slowly progressive or low-burden relapse, there may be time to try DLI (donor lymphocyte infusion) or achieve deeper remission with CAR-T or salvage chemotherapy before committing to a second transplant. For rapidly progressive disease, the priority is stabilisation. The decision is made by the medical team on a case-by-case basis — a second opinion from an experienced transplant centre is strongly advisable.
Does the donor change for a second transplant?
In most cases, yes. When relapse occurs after an allogeneic transplant, the immune system of the original donor has failed to control the disease — either because of insufficient graft-versus-leukaemia (GvL) effect or because the disease has escaped immune control. A different donor — often a haploidentical family member if the first donor was a matched sibling or unrelated donor — is frequently used for the second transplant to introduce a new immune response. Switching donor type is part of the transplant strategy, not a failure of the original plan.
What is DLI and when is it used instead of a second transplant?
DLI (donor lymphocyte infusion) involves infusing additional lymphocytes from the original transplant donor to boost the graft-versus-leukaemia (GvL) effect. It is most useful for patients who have relapsed late after transplant, have a functioning graft still present, and have low-burden or slowly progressive disease. DLI is not typically effective for rapid or high-burden relapse, and carries a risk of inducing or worsening GvHD. It may be used as a bridge or stabilisation measure before a second transplant, or as a definitive intervention in appropriate cases.
Is CAR-T cell therapy an option after a failed bone marrow transplant?
For children with B-cell acute lymphoblastic leukaemia (B-ALL) who relapse after transplant, CAR-T cell therapy targeting CD19 or CD22 is a recognised treatment pathway — and may be used as a bridge to a second transplant if durable remission is achieved. China has multiple NMPA-approved CAR-T products for paediatric B-ALL relapse. Eligibility for CAR-T after transplant requires careful assessment, including whether adequate CD19+ or CD22+ expression remains on leukaemic cells, organ function, and whether the patient is well enough to tolerate CAR-T infusion.
Medical disclaimer
ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All decisions regarding second bone marrow transplant, DLI, CAR-T, or any other treatment for a child must be made in consultation with qualified paediatric haematologists and transplant physicians who have reviewed the child's complete clinical records, disease history, and current status.
Request a paediatric haematology case review
A structured second opinion from an experienced Chinese paediatric transplant team — reviewing existing records, evaluating second transplant candidacy, donor options, CAR-T eligibility, and DLI appropriateness — without requiring your family to travel first.
Request a case reviewFor relapse after transplant, graft failure, second transplant decisions, and complex paediatric haematology cases.